SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Press Releases
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
March 10, 2025
 · 
15 min read
Press Releases
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 4, 2025
 · 
21 min read
Press Releases
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 27, 2025
 · 
14 min read
Press Releases
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
February 26, 2025
 · 
1 min read
Press Releases
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 18, 2025
 · 
14 min read
Press Releases
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
February 12, 2025
 · 
6 min read
Press Releases
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
January 14, 2025
 · 
16 min read
Press Releases
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
 · 
1 min read
Press Releases
TG Therapeutics to Participate in the Evercore HealthCONx Conference
December 2, 2024
 · 
1 min read
Press Releases
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
November 21, 2024
 · 
14 min read
Press Releases
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
November 5, 2024
 · 
20 min read
Press Releases
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
November 1, 2024
 · 
1 min read
Opioid health risk and medical crisis with a prescription painkiller addiction epidemic concept as a group of people running away from a dangerous falling bridge of pills as a medicine addict problem with 3D illustration elements.
FDA
5 Accelerated Approvals Gone Wrong
October 14, 2024
 · 
7 min read
 · 
Heather McKenzie
Press Releases
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
September 18, 2024
 · 
15 min read
Press Releases
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
September 18, 2024
 · 
16 min read
Press Releases
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
September 5, 2024
 · 
14 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS